BlackRock Discloses 5.1% Passive Stake in BioAtla
Ticker: BCAB · Form: SC 13G · Filed: Jan 29, 2024 · CIK: 1826892
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, SC-13G, bio-pharma
TL;DR
**BlackRock just revealed a 5.1% stake in BioAtla, signaling institutional interest.**
AI Summary
BlackRock, Inc. reported on January 29, 2024, that as of December 31, 2023, it beneficially owned 3,369,825 shares of BioAtla, Inc.'s common stock, representing 5.1% of the company. This filing indicates BlackRock's passive investment in BioAtla, meaning they don't intend to influence management. For investors, this shows a major institutional investor has a significant stake, which can be seen as a vote of confidence, but also means BlackRock could sell shares without needing to disclose their intentions beforehand, potentially impacting the stock price.
Why It Matters
This filing confirms a major institutional investor, BlackRock, holds a significant stake in BioAtla, which can influence investor perception and stock stability.
Risk Assessment
Risk Level: low — This is a routine disclosure of a passive investment by a large institutional investor, indicating no immediate red flags or aggressive actions.
Analyst Insight
Investors should note BlackRock's passive 5.1% stake as a sign of institutional interest, but understand this doesn't imply active management involvement or a bullish signal beyond a standard portfolio allocation.
Key Numbers
- 3,369,825 — Shares Owned (Number of BioAtla common shares beneficially owned by BlackRock, Inc. as of December 31, 2023.)
- 5.1% — Ownership Percentage (The percentage of BioAtla, Inc.'s common stock owned by BlackRock, Inc., indicating a significant institutional stake.)
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person and institutional investor
- BioAtla, Inc. (company) — the subject company whose shares are being reported
- 3,369,825 (dollar_amount) — number of shares beneficially owned by BlackRock
- 5.1% (dollar_amount) — percentage of BioAtla's common stock owned by BlackRock
- December 31, 2023 (person) — date of the event requiring the filing
- January 29, 2024 (person) — date the SC 13G filing was made
Forward-Looking Statements
- BlackRock will maintain its passive investment in BioAtla for the foreseeable future. (BlackRock, Inc.) — high confidence, target: December 31, 2024
FAQ
Who is the reporting person in this SC 13G filing?
The reporting person is BlackRock, Inc., a major institutional investment manager, as stated in the 'FILED BY' section of the filing.
What is the subject company whose shares are being reported?
The subject company is BioAtla, Inc., identified under the 'SUBJECT COMPANY' section and as the 'Name of Issuer' in the Schedule 13G.
As of what date did the event requiring this filing occur?
The event requiring this filing occurred on December 31, 2023, as specified under 'Date of Event Which Requires Filing of this Statement' in the Schedule 13G.
How many shares of BioAtla, Inc. common stock does BlackRock, Inc. beneficially own?
BlackRock, Inc. beneficially owns 3,369,825 shares of BioAtla, Inc. common stock, as indicated in the summary of beneficial ownership on the cover page of the filing.
What percentage of BioAtla, Inc.'s common stock does BlackRock, Inc.'s ownership represent?
BlackRock, Inc.'s ownership represents 5.1% of BioAtla, Inc.'s common stock, as detailed in the summary of beneficial ownership on the cover page.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 29, 2024 by December 31, 2023 regarding BioAtla, Inc. (BCAB).